PLEASE NOTE : This is a development system.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Belimumab - Lupus nephritis
PAD Profile : Belimumab - Lupus nephritis
Brand Names Include :
Benlysta
Traffic Light Status
Status 1 of 1.
Guidelines
No guidelines returned.
Other Drugs
No drugs returned.
Other Indications
Additional Documents
No additional documents returned.
Committee Recommendations
Date
Committee Name
Narrative
14 October 2021
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)
This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined. It is recommended that clinicians contact their medicines management team for further information and advice before prescribing this drug.
Associated BNF Codes
10. Musculoskeletal and Joint Diseases
10.01.03. Rheumatic disease suppressant drugs